Shanghai Pharmaceuticals EBITDA vs. Price To Book
| 601607 Stock | 21.37 0.07 0.33% |
EBITDA | First Reported 2010-12-31 | Previous Quarter 14.6 B | Current Value 10.7 B | Quarterly Volatility 2.5 B |
For Shanghai Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Shanghai Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Shanghai Pharmaceuticals Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Shanghai Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Shanghai Pharmaceuticals Holding over time as well as its relative position and ranking within its peers.
Shanghai |
Shanghai Pharmaceuticals Price To Book vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Shanghai Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Shanghai Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Shanghai Pharmaceuticals Holding is number one stock in ebitda category among its peers. It also is number one stock in price to book category among its peers . The ratio of EBITDA to Price To Book for Shanghai Pharmaceuticals Holding is about 8,609,314,830 . At present, Shanghai Pharmaceuticals' EBITDA is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all model that can be used if you cannot value Shanghai Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shanghai Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shanghai Price To Book vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Shanghai Pharmaceuticals |
| = | 9.62 B |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Shanghai Pharmaceuticals |
| = | 1.12 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Shanghai Price To Book Comparison
Shanghai Pharmaceuticals is currently under evaluation in price to book category among its peers.
Shanghai Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Shanghai Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Shanghai Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Shanghai Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Shanghai Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | 9.6 B | 10 B | |
| Income Before Tax | 7.1 B | 7.4 B | |
| Net Income Applicable To Common Shares | 5.9 B | 6.2 B | |
| Net Income | 3.8 B | 2.2 B | |
| Income Tax Expense | 2.1 B | 2.2 B | |
| Net Income From Continuing Ops | 5.2 B | 5.4 B | |
| Total Other Income Expense Net | -1.5 B | -1.4 B | |
| Net Interest Income | -1.3 B | -1.3 B | |
| Interest Income | 461.8 M | 315.1 M | |
| Change To Netincome | 1.2 B | 1.4 B |
Shanghai Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Shanghai Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Shanghai Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Shanghai Pharmaceuticals' important profitability drivers and their relationship over time.
Use Shanghai Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Shanghai Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Shanghai Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Shanghai Pharmaceuticals Pair Trading
Shanghai Pharmaceuticals Holding Pair Trading Analysis
The ability to find closely correlated positions to Shanghai Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Shanghai Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Shanghai Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Shanghai Pharmaceuticals Holding to buy it.
The correlation of Shanghai Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Shanghai Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Shanghai Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Shanghai Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Shanghai Pharmaceuticals position
In addition to having Shanghai Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Beer and Liquor Thematic Idea Now
Beer and Liquor
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Beer and Liquor theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beer and Liquor Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Shanghai Stock
To fully project Shanghai Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Shanghai Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Shanghai Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.